Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EmbraceRX vs Royal Medical Center

EmbraceRX
Graded #362

Higher grade

vs+9.200000000000003
Royal Medical Center
Graded #492

Lower grade

The verdict

EmbraceRX takes it — 58.6/100 to 49.4/100.

EmbraceRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EmbraceRX (Embrace Rx) is a clinician-guided telehealth platform offering pharmacy-compounded medications prescribed online, partnered with the Samaritan MD physician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbraceRX +23
45
22
Dose & formulationEmbraceRX +14
56
42
Clinical oversightEmbraceRX +14
76
62
Labs & monitoringRoyal Medical Center +34
52
86
FulfillmentEmbraceRX +25
73
48
Contract termsEven
55
55
EmbraceRX · left barRoyal Medical Center · right bar

The numbers

MetricEmbraceRXRoyal Medical Center
WeighScore58.6/10049.4/100
GradeCC
Scorecard rank#362#492
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosed$450/mo (2.5 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
EmbraceRX

Graded #362 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard